Carl Zeiss Meditec AG
Global website (English)
back
Carl Zeiss Meditec AG
recommended searches
popular searches

Carl Zeiss Meditec AG share

Investing in Carl Zeiss Meditec AG is an investment in the future of the health sector. We drive the development of leading-edge technology and make it available for applications in the field of: ophthalmology, neurosurgery, ENT surgery, dental applications and systems for intraoperative radiotherapy.

Quotes, Charts & Orderbook

Security Identification Numbers

Stock exchange abbreviation

AFX

ISIN

DE0005313704

Reuters Identification Code (RIC)

AFXG.F (exchange floor)
AFXG.DE (XETRA)

Bloomberg

AFX GR

Key Facts at a Glance

  • ISIN

    DE0005313704

    Trading Segment

    Prime Standard

    Designated Sponsors

    ODDO BHF Corporates & Markets AG

    Paying Agent

    Commerzbank AG

    Share Capital

    €89,440,570.00

    Admitted Capital

    €89,440,570.00

    Category and Nominal Value

    No-par value bearer shares at a nominal value of €1.00 per share

    Stock Markets

    Deutsche Börse in Frankfurt (XETRA and exchange floor, “Parkett”)
    Regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and Stuttgart

    Capital Measures

    23-Mar-2017:
    Increase of the share capital of €89,309,610.00
    against cash contribution by €8,130,960.00 (approx. 10%) to
    €89,440,570.00; subscription rights of shareholders were excluded.

    26-Oct-2006:
    Increase of the share capital of €32,523,844.00 (divided into 32,523,844 no-par value shares) by €48,785,766.00 to €81,309,610.00 (divided into 81,309,610 no-par value shares); capital increase with subscription rights and against contributions in kind and cash contributions.

    10-May-2005:
    Increase of the share capital of €29,682,182.00 against cash contribution by €2,841,662.00 (approx. 10%) to €32,523844.00; subscription rights of shareholders were excluded.

    01-Feb-2005:
    Increase of the share capital of €28,416,628.00 against contribution in kind by €1,265,553.00
    (4.45%) to €29,682,182.00; subscription rights of shareholders were excluded;
    capital increase was part of the acquisition of the majority holding in IOLTech S.A.

    18-Sep-2003:
    Increase of the share capital of €25,833,300.00 against cash contribution by €2,583,329.00
    (10%) to €28,416,629.00; subscription rights of shareholders were excluded.
  • 2021/22
    2020/21
    2019/20
    2018/19
    2017/18
    2016/17

    XETRA

    Year-end price (€1)

    107.45

    166.05

    108.00

    104.60

    72.50

    44.17

    Year high (€1)

    191.05

    199.05

    121.40

    108.70

    76.60

    47.45

    Year low (€1)

    101.75

    105.14

    69.70

    61.00

    44.85

    31.00

    Year average (€)
      

    141.67

    142.65

    98.18

    81.80

    56.91

    39.70

    Daily order book turnover (XETRA) in fiscal year

    in €
      

    15,367,421

    14,817,336

    16,090,137

    13,264,306.00

    4,988,993

    3,430,556
      

    Shares
      

    109,627

    105,938

    167,107

    162,154

    85,818

    86,412

    Number of shares as of 30 September
    (million shares)

    89.4

    89.4

    89.4

    89.4

    89.4

    89.4

    Market capitalization as of 30 September
    (€m)

    9,610.40

    14,851.60

    9,659.6

    9,355.5

    6,484.4

    3,950.1

    Earnings per share (€)

    3.29

    2.64

    1.37

    1.79

    1.41

    1.57

    Dividend per share (€)

    1.10

    0.90

    0.5 3)

    0.653)

    0.552)

    0.552)

    Dividend yield (%)1)

    1.0

    0.5

    0.5

    0.6

    1.24

    1.62

  • Bank/Analyst

    Current Rating

    Date

    Price Target

    KeplerCheuvreux
    Oliver Reinberg

    Reduce

    24-11-2023

    85.00 €

    ALPHAVALUE
    Anas Patel

    Buy

    23-11-2023

    118.00 €

    UBS
    Graham Doyle

    Neutral

    20-10-2023

    87.00 €

    Hauck & Aufhäuser
    Alexander Galitsa

    Buy

    12-10-2023

    140.00 €

    LBBW
    Volker Stoll

    Buy

    27-09-2023

    112.00 €

    Alster Research
    Harald Hof

    Buy

    22-09-2023

    100.00 €

    HSBC
    Sezgi Oezener

    Buy

    05-09-2023

    119.00 €

    Bankhaus Metzler
    Alexander Neuberger

    Hold

    16-08-2023

    90.00 €

    EQUI.TS GmbH
    Thomas Schießle

    Buy

    07-08-2023

    115.00 €

    Deutsche Bank AG
    Falko Friedrichs

    Hold

    07-08-2023

    100.00 €

    ODDO BHF
    Oliver Metzger

    Neutral

    04-08-2023

    115.00 €

    Berenberg Bank
    Sam England

    Hold

    04-08-2023

    110.00 €

    Bank of America Meryll Lynch
    Julien Ouaddour

    Neutral

    10-05-2023

    115.00 €

    DZ Bank
    Sven Kürten

    Buy

    06-03-2023

    155.00 €

    Morningstar
    Aaron Degagne

    09-08-2021

    64.00 €

    Nord/LB
    Holger Fechner

    Buy

    26-05-2021

    172.00 €

    Please note: Banks and securities firms use different terms for their equity ratings. The information contained in the table is based on publicly available sources that we consider reliable but for which we do not assume any liability.

    In particular, we do not guarantee that the information is complete, accurate or up-to-date. All ratings are based on opinions given by the analysts in question. These do not necessarily reflect the opinion of Carl Zeiss Meditec AG. The assessments may change at any time without prior notice. Exemption from liability applies to Carl Zeiss Meditec AG; it does not refer to the correct rendering of the information based on external sources, in particular public sources.

    Analyst assessments relating to Carl Zeiss Meditec AG shares are only revised each quarter and are therefore not continually updated.
      

  • ZEISS Shareholder Structure

    ZEISS Shareholder Structure

    Carl Zeiss Meditec AG's subscribed capital is composed of 89,440,570 ordinary shares, each with a theoretical par value of €1 per share. The ZEISS Group holds around 59% of the shares. According to our knowledge, the remaining 41% are in free float.

Request investor information

Investor Update

Form is loading...

Your data

If you want to have more information on data processing at ZEISS please refer to our data privacy notice.

  • 1

    As of the end of FY 30 September
  • 2

    Amount of dividend proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG.
  • 3

    Amount of dividend proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG.
  • 4

    Until FY 2016/17 ratio of dividend per share to opening price for the respective fiscal year, from FY 2017/18 ratio of dividend per share to closing rate on 30 September.